BRPI0408522A - uso de um inibidor de trombina de baixo peso molecular ou de um seu derivado farmaceuticamente aceitável, métodos de terapia de redução de colesterol e de tratamento de hipercolestrolemia, hiperlipoproteinemia e/ou hipertrigliceridemia, produto combinado, e, formulação farmacêutica para uso na terapia de redução de colesterol - Google Patents
uso de um inibidor de trombina de baixo peso molecular ou de um seu derivado farmaceuticamente aceitável, métodos de terapia de redução de colesterol e de tratamento de hipercolestrolemia, hiperlipoproteinemia e/ou hipertrigliceridemia, produto combinado, e, formulação farmacêutica para uso na terapia de redução de colesterolInfo
- Publication number
- BRPI0408522A BRPI0408522A BRPI0408522-1A BRPI0408522A BRPI0408522A BR PI0408522 A BRPI0408522 A BR PI0408522A BR PI0408522 A BRPI0408522 A BR PI0408522A BR PI0408522 A BRPI0408522 A BR PI0408522A
- Authority
- BR
- Brazil
- Prior art keywords
- cholesterol
- therapy
- pharmaceutically acceptable
- molecular weight
- low molecular
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 6
- 235000012000 cholesterol Nutrition 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 title abstract 2
- 229940122388 Thrombin inhibitor Drugs 0.000 title abstract 2
- 239000003868 thrombin inhibitor Substances 0.000 title abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 title 1
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 title 1
- 208000006575 hypertriglyceridemia Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000007592 Apolipoproteins Human genes 0.000 abstract 1
- 108010071619 Apolipoproteins Proteins 0.000 abstract 1
- 102000004895 Lipoproteins Human genes 0.000 abstract 1
- 108090001030 Lipoproteins Proteins 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0306615.6A GB0306615D0 (en) | 2003-03-22 | 2003-03-22 | New use |
| PCT/SE2004/000417 WO2004082702A1 (en) | 2003-03-22 | 2004-03-19 | Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0408522A true BRPI0408522A (pt) | 2006-03-07 |
Family
ID=9955311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0408522-1A BRPI0408522A (pt) | 2003-03-22 | 2004-03-19 | uso de um inibidor de trombina de baixo peso molecular ou de um seu derivado farmaceuticamente aceitável, métodos de terapia de redução de colesterol e de tratamento de hipercolestrolemia, hiperlipoproteinemia e/ou hipertrigliceridemia, produto combinado, e, formulação farmacêutica para uso na terapia de redução de colesterol |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20060183692A1 (https=) |
| EP (1) | EP1608311B1 (https=) |
| JP (1) | JP2006520813A (https=) |
| KR (1) | KR20050114237A (https=) |
| CN (1) | CN1761479A (https=) |
| AT (1) | ATE475417T1 (https=) |
| AU (1) | AU2004222409B2 (https=) |
| BR (1) | BRPI0408522A (https=) |
| CA (1) | CA2517191A1 (https=) |
| DE (1) | DE602004028348D1 (https=) |
| ES (1) | ES2346969T3 (https=) |
| GB (1) | GB0306615D0 (https=) |
| MX (1) | MXPA05010159A (https=) |
| NO (1) | NO20054285L (https=) |
| NZ (1) | NZ542505A (https=) |
| WO (1) | WO2004082702A1 (https=) |
| ZA (1) | ZA200507614B (https=) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1237518B (it) * | 1989-11-24 | 1993-06-08 | Renato Conti | Eparine supersolfatate |
| JP3140790B2 (ja) * | 1996-04-23 | 2001-03-05 | メルク エンド カンパニー インコーポレーテッド | ピラジノン系トロンビン阻害薬 |
| WO1998011896A1 (en) * | 1996-09-18 | 1998-03-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
| US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| AR023510A1 (es) * | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
| GB0014136D0 (en) * | 2000-06-10 | 2000-08-02 | Astrazeneca Ab | Combination therapy |
| US6462021B1 (en) * | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
| AR035216A1 (es) * | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| AU2003270861A1 (en) * | 2002-10-02 | 2004-04-23 | Bristol-Myers Squibb Company | Novel combination of a factor xa inhibitor and clopidogrel |
| US7470538B2 (en) * | 2002-12-05 | 2008-12-30 | Case Western Reserve University | Cell-based therapies for ischemia |
| US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
-
2003
- 2003-03-22 GB GBGB0306615.6A patent/GB0306615D0/en not_active Ceased
-
2004
- 2004-03-19 KR KR1020057017258A patent/KR20050114237A/ko not_active Ceased
- 2004-03-19 MX MXPA05010159A patent/MXPA05010159A/es not_active Application Discontinuation
- 2004-03-19 US US10/550,154 patent/US20060183692A1/en not_active Abandoned
- 2004-03-19 DE DE602004028348T patent/DE602004028348D1/de not_active Expired - Lifetime
- 2004-03-19 JP JP2006507972A patent/JP2006520813A/ja active Pending
- 2004-03-19 ES ES04722129T patent/ES2346969T3/es not_active Expired - Lifetime
- 2004-03-19 CN CNA2004800072860A patent/CN1761479A/zh active Pending
- 2004-03-19 AT AT04722129T patent/ATE475417T1/de not_active IP Right Cessation
- 2004-03-19 BR BRPI0408522-1A patent/BRPI0408522A/pt not_active IP Right Cessation
- 2004-03-19 CA CA002517191A patent/CA2517191A1/en not_active Abandoned
- 2004-03-19 NZ NZ542505A patent/NZ542505A/en unknown
- 2004-03-19 AU AU2004222409A patent/AU2004222409B2/en not_active Ceased
- 2004-03-19 WO PCT/SE2004/000417 patent/WO2004082702A1/en not_active Ceased
- 2004-03-19 EP EP04722129A patent/EP1608311B1/en not_active Expired - Lifetime
-
2005
- 2005-09-16 NO NO20054285A patent/NO20054285L/no not_active Application Discontinuation
- 2005-09-20 ZA ZA200507614A patent/ZA200507614B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004222409A1 (en) | 2004-09-30 |
| CA2517191A1 (en) | 2004-09-30 |
| MXPA05010159A (es) | 2005-11-16 |
| HK1084329A1 (en) | 2006-07-28 |
| EP1608311A1 (en) | 2005-12-28 |
| JP2006520813A (ja) | 2006-09-14 |
| ZA200507614B (en) | 2006-06-28 |
| GB0306615D0 (en) | 2003-04-30 |
| NO20054285L (no) | 2005-10-20 |
| CN1761479A (zh) | 2006-04-19 |
| NO20054285D0 (no) | 2005-09-16 |
| KR20050114237A (ko) | 2005-12-05 |
| EP1608311B1 (en) | 2010-07-28 |
| DE602004028348D1 (de) | 2010-09-09 |
| US20060183692A1 (en) | 2006-08-17 |
| ES2346969T3 (es) | 2010-10-22 |
| NZ542505A (en) | 2009-01-31 |
| ATE475417T1 (de) | 2010-08-15 |
| WO2004082702A8 (en) | 2005-03-24 |
| WO2004082702A1 (en) | 2004-09-30 |
| AU2004222409B2 (en) | 2007-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grainger et al. | Medical management of osteoarthritis of the knee and hip joints | |
| Yamasaki et al. | Tranexamic acid reduces postoperative blood loss in cementless total hip arthroplasty | |
| Goyal et al. | Intravenous vs intra-articular tranexamic acid in total knee arthroplasty: a randomized, double-blind trial | |
| McConnell et al. | Reducing blood loss in primary knee arthroplasty: a prospective randomised controlled trial of tranexamic acid and fibrin spray | |
| AR020001A1 (es) | COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO | |
| AR031117A1 (es) | Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica | |
| CO5690611A2 (es) | Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos | |
| CY1112981T1 (el) | Μεθοδος και συνθεση για την αγωγη της ρινιτιδας | |
| BR0111591A (pt) | Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes | |
| BR0314907A (pt) | Método para tratamento de resistência à insulina, inìcio de diabetes em adultos e sìndrome metabólica x e uso de (suvs) | |
| Mushtaq et al. | Non-surgical treatment of osteoarthritis-related pain in the elderly | |
| BR0109753A (pt) | Combinação farmacêutica, formulação farmacêutica, conjunto de partes, método para tratamento profilático ou terapêutico de um paciente que sofre de, ou é suscetìvel a, aterosclerose, e, usos de uma formulação, de uma combinação, ou de um conjunto de partes | |
| BR0007452A (pt) | Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação | |
| Vaz-da-Silva et al. | Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study | |
| BRPI0408522A (pt) | uso de um inibidor de trombina de baixo peso molecular ou de um seu derivado farmaceuticamente aceitável, métodos de terapia de redução de colesterol e de tratamento de hipercolestrolemia, hiperlipoproteinemia e/ou hipertrigliceridemia, produto combinado, e, formulação farmacêutica para uso na terapia de redução de colesterol | |
| BRPI0516810A (pt) | uso de conjugados de lipìdios no tratamento de doenças | |
| BR0307703A (pt) | Composições de medicamentos na base de agentes anticolinérgicos e inibidores de quinase de egfr | |
| Eriksson et al. | A New Oral Aniticoagulant, Dabigatran Etexilate, Is Effective and Safe in Preventing Venous Thromboembolism after Total Knee Replacement Surgery (The RE-MODEL Trial). | |
| Izumi et al. | CYP3A-mediated drug interaction profile of Bruton tyrosine kinase inhibitor, acalabrutinib | |
| NO20065657L (no) | Filmformet ostriol-inneholdende medikament for oral administrasjon | |
| Lassen et al. | Rivaroxaban-An Oral, Direct Factor Xa Inhibitor-for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial. | |
| Dallongeville et al. | Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein (a). European Fluvastatin Study Group | |
| Levy et al. | Lack of Clinically Significant Interactions Between the Subcutaneously Administered Direct Thrombin Inhibitor Desirudin and Orally Administered Warfarin Upon the International Normalized Ratio. | |
| US20110104253A1 (en) | Agent for intra-articular injection | |
| Davidson et al. | 303 Incremental Benefit of Atherogenic Cholesterol Reduction with Obicetrapib Administered with Moderate-Intensity Statins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |